arrow
S

Stuart K. Roberts

monash university
H指数:61
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gaps in the Cascade of Care Contribute to Poor Liver Cancer Outcomes Among People Living With Hepatitis B: A Multicenter Observational Cohort Study

乙型肝炎患者护理链中的缺口导致肝癌预后不良:一项多中心观察性队列研究

2026-09-070
OAAI
Healthcare costs of managing MAFLD are mostly driven by hospitalisation and advanced fibrosis: cost metabolic (dysfunction)-associated fatty liver disease analysis from a tertiary-care, multi-disciplinary MAFLD clinic

管理MAFLD的医疗保健成本主要由住院治疗和肝纤维化进展驱动:来自三级转诊多学科MAFLD诊所的代谢(功能障碍)相关脂肪肝疾病成本分析

2026-05-010
OAAI
Early-Stage Australian HCC Patients Treated at Tertiary Centres Show Comparable Survival Across Metropolitan and Non-Metropolitan Residency

在三级中心治疗的早期澳大利亚肝癌患者,其城市与非城市居住区的生存率相当

Livers
IF2.4
2026-01-040
OA
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study

Younossi, Z.M.; de Avila, L.; Petta, S.; Hagström, H.; Kim, S.U.; Nakajima, A.; Crespo, J.; Castera, L.; Alkhouri, N.; Zheng, M.H.; 等. MASLD的纤维化、临床事件及死亡率的预测因素:全球MASLD研究的数据. 肝病学 2025. [Google Scholar] [CrossRef]

2025-11-013
PRE
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study

非侵入性试验在MASLD中的全球表现:G-MASLD研究的见解

2025-10-010
PRE
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations

澳大利亚高风险人群肝细胞癌筛查临床实践指南:推荐意见摘要

2025-09-210
OAAI
Genetic Variants, Metabolic Dysfunction-Associated Fatty Liver Disease, and Major Health Outcomes in Older Adults

遗传变异、代谢功能障碍相关脂肪肝以及老年人主要健康结局

2025-08-210
PRE
Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary

代谢功能障碍相关脂肪性肝病在初级保健中的评估:共识声明摘要

2025-07-280
OAAI
Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population

脂肪变性无创检测能准确预测代谢功能障碍相关脂肪性肝病,而无创纤维化检测则不足:美国成人人群验证

2025-07-130
OA